Merck & Co.'s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan
CompanyDrug

Merck & Co.’s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan

Visirna Therapeutics Announces Positive Phase III Results for Plozasiran in FCS Treatment
CompanyDrug

Visirna Therapeutics Announces Positive Phase III Results for Plozasiran in FCS Treatment

ROBO Medical's Innovative Gastrointestinal Endoscopic Instrument Gains NMPA Approval
CompanyMedical Device

ROBO Medical’s Innovative Gastrointestinal Endoscopic Instrument Gains NMPA Approval

Basilea Pharmaceutica Cresemba Asia Pacific Sales
CompanyDeals

Basilea Pharmaceutica Marks Milestone as Cresemba Sales Soar in Asia Pacific

Phenomenex Inaugurates China R&D Center to Advance Danaher's "Launching China" Strategy
Company

Phenomenex Inaugurates China R&D Center to Advance Danaher’s “Launching China” Strategy

BMS's Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma
CompanyDrug

BMS’s Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma

Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline
CompanyDeals

Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline

Life Molecular Imaging Launches Neuraceq in Hong Kong for Alzheimer's Detection
CompanyDrug

Life Molecular Imaging Launches Neuraceq in Hong Kong for Alzheimer’s Detection

Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study
CompanyDrug

Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study

Inari Medical Wins NMPA Approval for Thrombectomy Stent System in China
CompanyMedical Device

Inari Medical Wins NMPA Approval for Thrombectomy Stent System in China

Jiangsu Hengrui Pharmaceuticals' Tegileridine Approved for Postoperative Pain Management
CompanyDrug

Jiangsu Hengrui Pharmaceuticals’ Tegileridine Approved for Postoperative Pain Management

Doma Biopharmaceutical's HER3-MUC1 Targeted ADC DM002 Receives NMPA Clinical Approval
CompanyDrug

Doma Biopharmaceutical’s HER3-MUC1 Targeted ADC DM002 Receives NMPA Clinical Approval